ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
33 announcements
NSE rejected Gufic Biosciences' waiver application regarding a ₹1.72 lakh penalty for Regulation 17(1A) non-compliance. The company will pay the fine by October 03, 2026.
Gufic Biosciences announced that CRISIL Ratings has reaffirmed its credit ratings on the company's total bank loan facilities of ₹516 Crore.
Gufic Biosciences held its 42nd Annual General Meeting on September 4, 2026, where shareholders adopted financial statements and approved the final dividend declaration.
Gufic Biosciences Limited announced the promotions of Ms. Ami Shah to Head-Legal and Mr. Pinak Padhya to President of Sales & Marketing, effective September 2, 2026.
Gufic reports strong Q1 FY27 growth, driven by Indore plant ramp-up and expansion into high-margin complex injectables like GLP-1 (Semaglutide) and Botulinum Toxin.
Gufic reported Q1 FY27 revenue of ₹260.8 Cr (+15% YoY) with EBITDA margins expanding to 18.09%. Strategy pivots toward IP-owned complex injectables and scaling the new Indore facility.
Gufic Biosciences will incorporate a new subsidiary, Gufic Philippines Inc, for ₹0.24 Crore. The entity will support the company's pharmaceutical business expansion in the Philippines.
Gufic Biosciences will incorporate a new subsidiary, Gufic Philippines Inc., to expand pharmaceutical distribution. The company approved a cash investment of approximately ₹2.4 Crore.
Gufic Biosciences will incorporate a subsidiary, 'Gufic Philippines Inc.', investing up to USD 250,000 (~₹2.38 Crore) to expand pharmaceutical operations in the Philippines.
Gufic BioSciences Ltd reported revenue from operations of ₹260.8 Cr (+16.6% YoY) and net profit of ₹22.3 Cr (+70.2% YoY) for Q1 FY27.
Gufic Biosciences Ltd has released its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26. The report details the company's commitment to ESG standards.
Gufic Biosciences Limited has filed its Annual Report for FY 2025-26, along with the notice for its 42nd Annual General Meeting scheduled for September 4, 2026.
Gufic Biosciences will hold its 42nd AGM on September 4, 2026, via video conferencing. The register of members will be closed from August 29, 2026.
Gufic Biosciences Limited has scheduled a board meeting for August 14, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026.
Gufic Biosciences Limited has re-appointed Mr. Pankaj Jayakumar Gandhi as Executive Director for a term of 60 months effective September 7, 2026.
Gufic Biosciences' Board approved the re-appointment of Mr. Pankaj Jayakumar Gandhi as Whole Time Director for a 5-year term, effective September 7, 2026.
Gufic Biosciences Ltd has submitted its quarterly shareholding pattern for the period ending June 30, 2026, in compliance with SEBI regulations.
Gufic delivered record Q4 FY26 revenue of ₹252cr with EBITDA margins expanding to 17.7%. Management is pivoting to an IP-led international model and scaling the new Indore facility.
Gufic Biosciences clarified its share subscription in Saraswat Co-operative Bank is for regulatory borrower-linkage requirements. The transaction maintains existing credit facilities without changing bank control.
Gufic delivered its strongest ever quarter in Q4FY26, driven by Indore facility break-even and a strategic shift in the international business model towards holding its own marketing authorizations.
Gufic Biosciences reported Q4 FY26 revenue of ₹252.1 cr and PAT of ₹20.5 cr. Strategy focuses on scaling the Indore facility and transitioning to an IP-owned international model.
Gufic Biosciences appointed Mrs. Saroj R. Kirdolia as Internal Auditor and re-appointed M/s. Poddar & Co. as Cost Auditor. Both appointments cover the Financial Year 2026-27.
Gufic Biosciences approved a ₹5.75 Crore equity investment in Saraswat Co-operative Bank Limited. The move strengthens their existing banking relationship and broader treasury management strategy.
Gufic Biosciences recommended a final dividend of Re. 0.10 per equity share for financial year 2025-26. The distribution is subject to shareholder approval at the upcoming AGM.
Gufic Biosciences reported consolidated total income of ₹946.66 Crore for FY26. The board also recommended a final dividend of ₹0.10 per equity share.
Gufic BioSciences Ltd reported revenue from operations of ₹251.8 Cr (+22.8% YoY) and net profit of ₹21.9 Cr (+184.4% YoY) for Q4 FY26.
Gufic Biosciences reported audited FY26 results and recommended a 10% final dividend. The Board also approved a ₹5.75 Crore equity investment in Saraswat Co-operative Bank.
Gufic Biosciences submitted its Annual Secretarial Compliance Report for the financial year 2026. The report confirms overall regulatory compliance with noted historical fine payments.
Gufic Biosciences scheduled a May 29 board meeting to approve FY2026 audited results and consider a final dividend. Trading remains closed until 48 hours post-declaration.
Gufic Biosciences Limited has completed a further investment of ₹0.47 Crore (USD 50,000) in Selvax Pty Ltd. The transaction involved subscribing to 378,350 ordinary shares at AUD 20 cents per share. This strategic investment strengthens Gufic's international portfolio and was finalized on April 28, 2026.